{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T05:20:19Z","timestamp":1720934419302},"reference-count":41,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The development of novel cellular therapies and bispecific T-cell-engaging antibodies is occurring at breakneck speed in multiple myeloma (MM). While groundbreaking, these agents have their unique logistical and toxicity issues and currently do not represent a curative approach. In this context, there continues to be an urgent need to develop novel, off-the-shelf immunotherapy approaches to add to the armamentarium. This article explores novel agents being investigated in combination with standard immunomodulatory drugs as well as next-generation cereblon E3 ligase modulators. These novel agents include drugs being repurposed from their use in other diseases as well as novel monoclonal antibodies. In addition, agents under development such as immunocytokines, immunotoxins, and natural killer-cell activators\/engagers are reviewed. These novel therapeutic strategies hold the promise of countermanding the immunosuppressive tumor microenvironment, leading to enhanced anti-MM activity.<\/jats:p>","DOI":"10.1182\/hematology.2022000335","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:08:41Z","timestamp":1670602121000},"page":"173-179","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma"],"prefix":"10.1182","volume":"2022","author":[{"given":"Sarah A.","family":"Holstein","sequence":"first","affiliation":[{"name":"Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"9","key":"2022120916075295400_hem2022000335C1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.18632\/oncotarget.655","article-title":"Bruton's tyrosine kinase: oncotarget in myeloma","volume":"3","author":"Tai","year":"2012","journal-title":"Oncotarget"},{"issue":"6","key":"2022120916075295400_hem2022000335C2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/bjh.15058","article-title":"Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results","volume":"180","author":"Richardson","year":"2018","journal-title":"Br J Haematol"},{"key":"2022120916075295400_hem2022000335C3","article-title":"Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and\/or refractory multiple myeloma: phase I trial results [published online ahead of print 30 April 2022]","author":"Ailawadhi","journal-title":"Hematol Oncol"},{"issue":"3","key":"2022120916075295400_hem2022000335C4","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/bjh.17282","article-title":"Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma","volume":"192","author":"Chen","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2022120916075295400_hem2022000335C5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bjh.16158","article-title":"JAK1\/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression","volume":"188","author":"Chen","year":"2020","journal-title":"Br J Haematol"},{"issue":"10","key":"2022120916075295400_hem2022000335C6","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1158\/1078-0432.CCR-19-1899","article-title":"A phase I study of ruxolitinib, lenalidomide, and steroids for patients with relapsed\/refractory multiple myeloma","volume":"26","author":"Berenson","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2022120916075295400_hem2022000335C7","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/bloodadvances.2018027227","article-title":"Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting","volume":"3","author":"Buettner","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"2022120916075295400_hem2022000335C8","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1080\/10428194.2020.1742900","article-title":"Repurposing leflunomide for relapsed\/refractory multiple myeloma: a phase 1 study","volume":"61","author":"Rosenzweig","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2022120916075295400_hem2022000335C9","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood-2019-126728","article-title":"Preclinical studies and phase I trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: a corticosteroid-free approach by targeting TGF-\u03b2 signaling pathway","volume":"134","author":"Malek","year":"2019","journal-title":"Blood"},{"issue":"suppl 15","key":"2022120916075295400_hem2022000335C10","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2021.39.15_suppl.8039","article-title":"Phase Ib trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: a corticosteroid- free approach by targeting TGF-\u03b2 signaling pathway","volume":"39","author":"Malek","year":"2021","journal-title":"J Clin Oncol"},{"key":"2022120916075295400_hem2022000335C11","first-page":"19","article-title":"Inhibition of S100A9 with tasquinimod demonstrates potent anti-tumor activity in pre-clinical models of multiple myeloma","author":"Lin","year":"2020"},{"issue":"9","key":"2022120916075295400_hem2022000335C12","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open- label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"2022120916075295400_hem2022000335C13","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"issue":"19","key":"2022120916075295400_hem2022000335C14","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMp1803602","article-title":"Immunotherapy combinations in multiple myeloma\u2014 known unknowns","volume":"379","author":"Gormley","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2022120916075295400_hem2022000335C15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/17474086.2020.1744432","article-title":"A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma","volume":"13","author":"Oriol","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2022120916075295400_hem2022000335C16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J Med Chem"},{"issue":"22","key":"2022120916075295400_hem2022000335C17","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1182\/blood.V128.22.1591.1591","article-title":"CC-220 is a potent cereblon modulating agent that displays anti-proliferative, pro-apoptotic and immunomodulatory activity on sensitive and resistant multiple myeloma cell lines","volume":"128","author":"Bjorklund","year":"2016","journal-title":"Blood"},{"issue":"suppl 15","key":"2022120916075295400_hem2022000335C18","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2019.37.15_suppl.8006","article-title":"First clinical (phase 1b\/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"37","author":"Lonial","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2022120916075295400_hem2022000335C19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/blood-2021-147704","article-title":"Iberdomide (IBER) in combination with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the dose-expansion phase of the CC-220-MM-001 trial","volume":"138","author":"Lonial","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022120916075295400_hem2022000335C20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1182\/blood-2021-151542","article-title":"Large-scale mass cytometry reveals significant activation of innate and adaptive immunity in bone marrow tumor microenvironment of iberdomide-treated myeloma patients","volume":"138","author":"Van Oekelen","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022120916075295400_hem2022000335C21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-137743","article-title":"First results of iberdomide (IBER; CC-220) in combination with dexamethasone (DEX) and daratumumab (DARA) or bortezomib (BORT) in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Van de Donk","year":"2020","journal-title":"Blood"},{"issue":"13","key":"2022120916075295400_hem2022000335C22","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J Med Chem"},{"issue":"suppl 15","key":"2022120916075295400_hem2022000335C23","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2020.38.15_suppl.8500","article-title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Richardson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2022120916075295400_hem2022000335C24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-137161","article-title":"Dose- and schedule-dependent immunomodulatory effects of the novel CELMoD agent CC-92480 in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Wong","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2022120916075295400_hem2022000335C25","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2021-147812","article-title":"CC-92480, a potent, novel cereblon E3 ligase modulator (CELMoD) agent, in combination with dexamethasone (DEX) and bortezomib (BORT) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): preliminary results from the phase 1\/2 study CC-92480-MM-002","volume":"138","author":"Richardson","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2022120916075295400_hem2022000335C26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"17","key":"2022120916075295400_hem2022000335C27","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2022120916075295400_hem2022000335C28","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1023\/A:1026548226770","article-title":"Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients","volume":"11","author":"Fritz","year":"2000","journal-title":"Ann Oncol"},{"issue":"9","key":"2022120916075295400_hem2022000335C29","doi-asserted-by":"crossref","first-page":"e0162472","DOI":"10.1371\/journal.pone.0162472","article-title":"Targeting attenuated interferon-\u03b1 to myeloma cells with a CD38 antibody induces potent tumor regression with reduced off-target activity","volume":"11","author":"Pogue","year":"2016","journal-title":"PLoS One"},{"issue":"suppl 1","key":"2022120916075295400_hem2022000335C30","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2021-148463","article-title":"Modakafusp alfa (TAK-573), an immunocytokine, shows clinical activity in patients with relapsed\/refractory multiple myeloma: updated results from a first-in-human phase 1 study","volume":"138","author":"Vogl","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022120916075295400_hem2022000335C31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-141219","article-title":"TAK-573, an anti-CD38\/attenuated IFN\u03b1 fusion protein, has clinical activity and modulates the IFN\u03b1 receptor (IFNAR) pathway in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Vogl","year":"2020","journal-title":"Blood"},{"issue":"suppl 13","key":"2022120916075295400_hem2022000335C32","article-title":"Abstract 2384: TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma [abstract]","volume":"79","author":"Willert","year":"2019","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"2022120916075295400_hem2022000335C33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-136928","article-title":"TAK-169, a novel recombinant immunotoxin specific for CD38, induces powerful preclinical activity against patient-derived multiple myeloma cells","volume":"136","author":"Bruins","year":"2020","journal-title":"Blood"},{"key":"2022120916075295400_hem2022000335C34","article-title":"Interim results of a phase 1 study of the novel engineered toxin body TAK-169 in patients with relapsed or refractory multiple myeloma [abstract]","volume":"9","author":"Kamur","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2022120916075295400_hem2022000335C35","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3389\/fimmu.2020.01155","article-title":"Targeted therapy with immunoconjugates for multiple myeloma","volume":"11","author":"Bruins","year":"2020","journal-title":"Front Immunol"},{"issue":"23","key":"2022120916075295400_hem2022000335C36","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"2022120916075295400_hem2022000335C37","article-title":"Restoring NK cell activities in multiple myeloma with IL-15 receptor agonist NKTR-255","author":"Fernandez","year":"2020"},{"key":"2022120916075295400_hem2022000335C38","doi-asserted-by":"crossref","first-page":"838406","DOI":"10.3389\/fimmu.2022.838406","article-title":"Half-life extended nanobody-based CD38-specific bispecific killercell engagers induce killing of multiple myeloma cells","volume":"13","author":"Hambach","year":"2022","journal-title":"Front Immunol"},{"issue":"suppl 1","key":"2022120916075295400_hem2022000335C39","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2019-130838","article-title":"A novel class of bifunctional immunotherapeutic that exploits a universal antibody binding terminus (uABT) to recruit endogenous antibodies to cell expressing CD38 demonstrate in vivo efficacy in three distinct animal models","volume":"134","author":"Bunin","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2022120916075295400_hem2022000335C40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CJI.0000000000000320","article-title":"BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma","volume":"43","author":"Wang","year":"2020","journal-title":"J Immunother"},{"issue":"suppl 1","key":"2022120916075295400_hem2022000335C41","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1182\/blood-2019-128749","article-title":"CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma","volume":"134","author":"Watkins-Yoon","year":"2019","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/173\/2021746\/173holstein.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/173\/2021746\/173holstein.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:08:59Z","timestamp":1670602139000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/173\/493492\/Beyond-the-cell-novel-noncellular-immunotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000335","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}